Oppenheimer raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $65 from $63 and keeps an Outperform rating on the shares.

After reaching a $6.01 billion deal with 3M to settle the largest mass tort litigation in U.S. history, lawyers for the ...

Many local pharmaceutical companies face high costs and struggle to meet international quality standards. According to the World Health Organization (WHO), fewer than 10% of medicines manufactured in ...

Analysts have recently evaluated Lexicon Pharmaceuticals and provided 12-month price targets. The average target is $9.2, ...

The United States Agency for International Development has announced a $2.3m commitment to procure 4.8 million doses of ...

During the last three months, 24 analysts shared their evaluations of Alnylam Pharmaceuticals ALNY, revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ...

Reports Q3 revenue $55.3M, consensus $41.93M. “2024 has been a significant year for Rigel, marked by the acquisition of GAVRETO, our ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Vertex Pharmaceuticals is in the process of getting a new painkiller approved. It just published some data that suggests the candidate will be quite profitable. But regulators still need to sign ...